The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...

weight loss drug Zepbound is no longer in shortage. Hims & Hers (NYSE:HIMS) markets compounded versions of rival Novo Nordisk’s (NVO) weight loss therapy semaglutide at a sharp discount to the ...

In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be ...

Compounding pharmacies and telehealth firms such as Hims & Hers had been allowed to produce hundreds of thousands of doses of copies of weight-loss drugs Wegovy and Eli Lilly’s Zepbound ...

Hims & Hers is a newfangled telehealth company that ... Then, on 5/20/24, HIMS metaphorically pushed harder on the launch button. It announced it would make GLP-1 injections available to its ...

Hims & Hers ... erode Hims & Hers' business. Now, the Texas lawsuit is ongoing, but as of today, there's no injunction forbidding the FDA from saying the shortage of Zepbound is over, like it ...

though still higher than the compounded versions Hims had been selling. Eli Lilly is following suit with a similar pricing strategy for Zepbound. With major insurers expanding coverage and direct ...